Global R&D Pipeline
My Favorite
Hot Targets:
CD28
Back
Total number of drugs
116
Phase II and later clinical stages
4.3%
Involving companies
129
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BND-67 | BND-67 | Monoclonal antibody | Neoplasms | CD28 inhibitors | Biond Biologics Ltd. | Biond Biologics Ltd. | IND Application | - | - | - | - | - | - | - | - | - | BND-67 | - | - | detail > | |
| KA-3003 | KA-3003 | Trispecific antibody | Neoplasms Urogenital Diseases | 4-1BB agonists CD28 inhibitors PSMA inhibitors | Kyinno Biotechnology Co., Ltd. | Kyinno Biotechnology Co., Ltd. | Preclinical | Preclinical | - | - | - | - | - | - | - | - | KA-3003 | - | - | detail > | |
| S-TILs | S-TILs | TIL therapy | Neoplasms | CD19 inhibitors CD28 agonists PD-1 inhibitors | The First Affiliated Hospital of Zhengzhou University | Beijing Chineo Medical Technology Co., Ltd | Preclinical | Preclinical | - | - | - | - | - | - | - | - | S-TILs | - | - | detail > | |
| HLX-3902 | HLX-3902 | Trispecific T-cell engager (TriTE) | Neoplasms Urogenital Diseases | CD28 agonists CD3 stimulants STEAP1 inhibitors | Shanghai Henlius Biotech, Inc. | Shanghai Henlius Biotech, Inc. | Preclinical | Preclinical | - | - | - | - | - | - | - | - | HLX-3902 | - | - | detail > | |
| KA-3001 | KA-3001 | Bispecific antibody | Neoplasms Urogenital Diseases | CD28 inhibitors PSMA inhibitors | Kyinno Biotechnology Co., Ltd. | Kyinno Biotechnology Co., Ltd. | Preclinical | Preclinical | - | - | - | - | - | - | - | - | KA-3001 | - | - | detail > | |
| IgGsp_CD28z STEAP1 CAR T | IgGsp_CD28z STEAP1 CAR T | CAR-T | Neoplasms Urogenital Diseases | CD28 agonists STEAP1 inhibitors | Oslo universitetssykehus HF | Oslo universitetssykehus HF | Preclinical | - | - | - | - | - | - | - | - | - | IgGsp_CD28z STEAP1 CAR T | - | - | detail > | |
| CC-312 | CC-312 | Trispecific T-cell engager (TriTE) | Neoplasms Immune System Diseases Hemic and Lymphatic Diseases Nervous System Diseases Skin and Musculoskeletal Diseases Other Diseases | CD19 inhibitors CD28 agonists CD3 stimulants | CytoCares Shanghai, Inc. | CytoCares Shanghai, Inc. | Phase 1 | Phase 1 | - | - | - | - | - | - | - | - | CC-312 | - | - | detail > | |
| Anti-CD28｜CD7 CAR-T (Baylor College of Medicine) | Anti-CD28｜CD7 CAR-T (Baylor College of Medicine) | Autologous CAR-T | Neoplasms Immune System Diseases Hemic and Lymphatic Diseases Other Diseases | CD28 modulators CD7 inhibitors | Baylor College of Medicine | Baylor College of Medicine | Phase 1 | - | - | - | - | - | - | - | - | - | Anti-CD28｜CD7 CAR-T (Baylor College of Medicine) | - | - | detail > | |
| CHM-1101 | CHM-1101 | Autologous CAR-T | Neoplasms Nervous System Diseases Other Diseases Digestive System Disorders Skin and Musculoskeletal Diseases Urogenital Diseases | CD19 inhibitors CD28 modulators CD3 modulators | City of Hope National Medical Center | Chimeric Therapeutics Ltd. (Australia) Chimeric Therapeutics Ltd. City of Hope National Medical Center | Phase 1 | - | - | - | - | - | - | - | - | - | CHM-1101 | - | - | detail > | |
| Anti-EGFR/CD28 bispecific antibody(Hengrui) | Anti-EGFR/CD28 bispecific antibody(Hengrui) | Bispecific antibody | Neoplasms | CD28 inhibitors EGFR antagonists | Shanghai Hengrui Pharmaceutical Co., Ltd. Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Preclinical | Preclinical | - | - | - | - | - | - | - | - | Anti-EGFR/CD28 bispecific antibody(Hengrui) | - | - | detail > |
Total 116 data
1
2
3
4
5
6
...
11
12
